---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-009213"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2025-02-03T23:59:59+00:00"
generated_at: "2026-05-27T04:01:48.825897+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# InMed selects IVT formulation for INM-089 in dry AMD; preclinical data shows 10x safety margin

## Summary
- Selected intravitreal (IVT) formulation for INM-089 as drug candidate for dry age-related macular degeneration (AMD).
- Preclinical studies demonstrated successful delivery at doses up to 10 times projected therapeutic level, indicating favorable PK and safety margin.
- Completed dose-ranging in vivo studies to guide dose selection for pivotal preclinical toxicology studies.
- Intravitreal injection is established method for drug delivery to back of eye; overcomes challenges of topical formulations.

## SEC filing metadata
- accession: 0001213900-25-009213
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2025-02-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390025009213/0001213900-25-009213-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390025009213/ea0229633-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-009213
- JSON: https://secwatch.observer/filing/0001213900-25-009213.json
- Plain text: https://secwatch.observer/filing/0001213900-25-009213.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.